2015 American Transplant Congress
Survival Benefit of Liver Transplant Among HIV+ Waitlist Candidates
Liver failure is the most common cause of non-AIDS related death among HIV+ patients, primarily due to high prevalence of co-infection with hepatitis C (HCV)…2015 American Transplant Congress
Development of a Risk Assessment Model for HIV Among Increased Risk Deceased Donors With Negative Nucleic Acid Testing
Centers for Disease Control and Prevention, Atlanta, GA.
Background: In 2013, guidelines for reducing the risk of HIV, hepatitis B and C disease transmission through organ transplants were released. These include criteria which…2015 American Transplant Congress
Racial Differences in Transplant and Waitlist Mortality Rates Among HIV+ Kidney Transplant Candidates
Kidney transplant (KT) is now a viable option for select HIV+ end-stage renal disease patients. As OPTN does not collect HIV status at waitlisting, no…2015 American Transplant Congress
Screening Recipients of Increased Risk Donor Organs: A Multicenter Study
Purpose: Policy mandates post-transplant (tx) evaluation of recipients of increased risk donor organs (ROIRDO). PHS guidelines recommend that screening include HIV & hepatitis C virus…2015 American Transplant Congress
Changing Demographics of HIV+ Liver Transplant Candidates
Liver transplant (LT) is considered a reasonable therapeutic option for certain HIV+ patients with end-stage liver disease (ESLD). As OPTN does not collect HIV status…2015 American Transplant Congress
Defining the Epidemiologic Landscape of HIV-Infected Deceased Donors in the United States
Surgery, Johns Hopkins University, Baltimore, MD.
The HIV Organ Policy Equity Act mandates research on the use of HIV-infected (HIV+) deceased donors (HIVDD) for transplantation in HIV+ recipients. The only data…2015 American Transplant Congress
Induction With ATG Is Not Associated With Increased Infections After Kidney Transplant Among HIV Positive Patients: Results of a National Study
1JHU, Baltimore; 2UAB, Birmingham.
Anti-thymocyte globulin (ATG) is widely used for induction, particularly for those at high risk for rejection. HIV+ kidney transplant (KT) recipients have 3 fold higher…2015 American Transplant Congress
Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Co-Infected Recipients: The “Real World” Experience
End stage liver disease is a frequent cause of mortality in patients with HIV. Though demonstrated in the NIH observational trial, the effectiveness of LT…2015 American Transplant Congress
Impact of Induction Therapy on Outcomes in HIV + Renal Transplant Recipients
Purpose: Kidney transplantation in HIV+ recipients has been complicated by higher than expected acute rejection rates (AR). Induction immunosuppression may or may not impact this…2015 American Transplant Congress
Survival Benefit of Kidney Transplant Among HIV+ Waitlist Candidates
Chronic diseases, such as end-stage renal disease (ESRD), are now the leading causes of death among HIV+ patients. Multiple studies have demonstrated the efficacy of…
American Transplant Congress abstracts